News & Events about Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) EVP Jeffrey Robert Ajer sold 49,000 shares of the companys stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $115.70, for a total value of $5,669,300.00. Following the completion of ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) has earned an average rating of Moderate Buy from the nineteen research firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on ...
Canaccord Genuity Group began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN Get Rating) in a report published on Wednesday, Marketbeat reports. The brokerage issued a hold rating and a $119.00 target price on the biotechnology companys stock. Several other equities ...
BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis BioMarin Announces Stable and Durable Annualized Bleed...
Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp? Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp? PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK, Jan. 5, 2023...